Closing comments on A.P. Pharma:
During my last post I covered a majority of the information I wanted to cover on A.P. Pharma’s anti-emetic drug, APF-530. Now I would like to conclude my analysis and present my thesis for investing in APPA.
Here are the key reasons for investing in APPA:
1.) The active compound in APF-530 (granesitron) has a [...]
Closing comments on A.P. Pharma:
Spectrum Pharmaceutical’s CEO Rajesh Shrotriya, M.D presented an overview of the company today in Las Vegas at the Noble Financial Conference. I wanted to view the presentation in order to see if I could get additional information that may have been overlooked during my previous reviews of this company. For those of you who haven’t [...]Continue reading...
The oncology market is the third largest pharmaceutical market, behind the cardiovascular and central nervous system (CNS) therapy markets, and is currently experiencing strong growth. Analysts predict that the sector will grow to $60 billion by 2010. The frequency and debilitating nature of chemotherapeutic side-effects are a huge problem that requires the discovery and development [...]Continue reading...
Let’s continue with our analysis of Spectrum Pharmaceuticals (SPPI), specifically reviewing their pipeline of drugs in development for readers that are interested in biotech stock investing.
Fusilev was approved in March 2008 as rescue therapy for osteosarcoma patients after receiving high-dose methotrexate (chemotherapy). Osteosarcoma is a malignant bone cancer afflicting individuals under the age of [...]
Spectrum Pharmaceuticals (SPPI) is a small cap biotech company that focuses on developing drugs in oncology and urology. Spectrum fits my investment criteria and warrants a thorough analysis. The company currently trades at a technology value (see previous posts on tech value) lower than any company I’ve come across over the past 8 years. In [...]Continue reading...
Bristol-Myers Squibb made an offer today to purchase Imclone Systems for $60 per share or $4.5 billion in cash. Bristol already owns about 17 percent of Imclone so today’s offer values Imclone at $5.2 billion.
The offer was a 30 percent premium over Wednesday’s closing price of $46.44 per share. Shares of Imclone closed at $63.93, [...]
After the news release of Roche’s merger proposal for the remaining stake in Genentech today, I thought the time was right to complete my previous post.
To reiterate, there were two important pieces of information that I found useful after completing my study. First, the loss in market cap amongst the small cap companies comprising the [...]
In my previous post I discussed a useful valuation metric applied to development stage biotech companies. I also stated that we would look at the results from a small study I completed on the change in total market cap of the companies comprising the two biotech indices over the past two years.
The purpose of the [...]
I’ve decided to make the effort to design a relatively simple study to determine the change in valuations of the biotech and pharma industries over the past two years. I find this type of analysis useful in my profession by comparing the changes in the major biotech indices and the aggregate market cap of the [...]Continue reading...